• Mashup Score: 10

    BACKGROUND: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply

    Tweet Tweets with this article
    • Advancing Clinical Trial Design for Non-Muscle Invasive #BladderCancer Thanks for your leadership on this @ElaineChangMD @US_FDA https://t.co/3CEfC3Oa3W @slernerbcmedu1 @MariaJRibal @FaltasLab @Jaleh_Fallah @sundeeponc @Vishalbmd @MaxKates @garysteinbergmd @MattGalsky… https://t.co/YWc5u10Q3Y